Menu
Search
|

Menu

Close
X

AMAG Pharmaceuticals Inc AMAG.OQ (NASDAQ Stock Exchange Global Select Market)

21.75 USD
-0.25 (-1.14%)
As of Jul 13
chart
Previous Close 22.00
Open 21.85
Volume 99,688
3m Avg Volume 195,540
Today’s High 22.40
Today’s Low 21.65
52 Week High 25.60
52 Week Low 11.93
Shares Outstanding (mil) 35.29
Market Capitalization (mil) 661.66
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.90 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
146
FY17
610
FY16
532
FY15
418
EPS (USD)
FY18
-2.194
FY17
-6.177
FY16
-0.158
FY15
0.787
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
1.12
5.73
Price to Book (MRQ)
vs sector
0.70
5.45
Price to Cash Flow (TTM)
vs sector
9.04
23.29
Total Debt to Equity (MRQ)
vs sector
81.25
16.72
LT Debt to Equity (MRQ)
vs sector
81.25
12.39
Return on Investment (TTM)
vs sector
-2.17
14.61
Return on Equity (TTM)
vs sector
-4.83
16.34

EXECUTIVE LEADERSHIP

Gino Santini
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
William Heiden
President, Chief Executive Officer, Director, Since 2017
Salary: $702,973.00
Bonus: $553,350.00
Edward Myles
Chief Financial Officer, Executive Vice President - Finance, Treasurer, Since 2017
Salary: $428,847.00
Bonus: $216,113.00
Elizabeth Bolgiano
Chief Human Resource Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Joseph Vittiglio
General Counsel, Executive Vice President, Legal Affairs and Quality and Secretary, Since 2017
Salary: $401,670.00
Bonus: $167,400.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1100 Winter St
WALTHAM   MA   02451-1427

Phone: +1617.4983300

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

SPONSORED STORIES